证券日报网讯汉森制药8月5日在互动平台回答投资者提问时表示，截至2025年7月31日，公司含信用账 户合并股东名册的股东总数为24，418户。 （文章来源：证券日报） ...

Group 1 - The company acknowledges the impact of national "anti-involution" and "medical procurement" policies on the industry, suggesting a positive influence on its operations and product effectiveness [1] - The company emphasizes its commitment to closely monitor industry trends and enhance its core competitiveness in response to these policies [1]

Group 1 - The core viewpoint of the articles highlights the significant progress made by Yiyang City in brand building, with three local brands recognized in national evaluations, indicating a strong competitive advantage in regional branding, traditional industries, and the pharmaceutical health sector [1][2] - The three brands that made the list are Anhua Black Tea, Hunan Shali Socks, and Hunan Hansen Pharmaceutical, showcasing Yiyang's differentiated competitive strengths in their respective fields [1] - Anhua Black Tea ranked 7th in the regional brand category, becoming one of the 36 regional brands with a value exceeding 10 billion yuan, and is positioned as a key player in rural revitalization [1][2] Group 2 - Yiyang's government has implemented a brand-strengthening strategy as a key driver for high-quality economic development, establishing a collaborative mechanism involving government guidance, departmental coordination, enterprise participation, and social involvement [2] - The market regulatory department in Yiyang has focused on enhancing brand value for enterprises by simplifying brand registration processes and providing one-on-one guidance, significantly improving efficiency in brand building [2] - Yiyang has actively promoted quality improvement initiatives, encouraging enterprises to pursue various certifications and providing comprehensive quality management support, which has strengthened brand awareness and contributed to the city's economic development [2]

证券代码：002412 证券简称：汉森制药 公告编号：2025-014 湖南汉森制药股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示 1．本次股东大会无否决、修改或新增议案的情况。 2．本次股东大会无变更以往股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1．会议召开时间 （1）现场会议时间：2025 年 5 月 21 日（星期三）14∶30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 21 日 9:15—9:25、9:30—11:30 和 13:00—15:00；通过深圳证券交 易所互联网投票系统进行网络投票的具体时间为 2025 年 5 月 21 日 9:15 至 2025 年 5 月 21 日 15:00 的任意时间。 5．会议主持人：公司董事长兼总裁刘正清先生 6．本次股东大会的召集、召开程序符合《公司法》《上市公司股东会规则》等 法律、法规、规范性文件以及《公司章程》的规定。 （二）股东出席会议情况 出席本次股东大会的股东及股东授 ...

湖南启元律师事务所 HUNAN QIYUAN LAW FIRM 湖南省长沙市芙蓉区建湘路 393 号 世茂环球金融中心 63 层 410000 Tel：(0731) 8295 3778 Fax：(0731) 8295 3779 http://www.qiyuan.com 湖南启元律师事务所 关于湖南汉森制药股份有限公司 2024 年年度股东大会的 法律意见书 致：湖南汉森制药股份有限公司 湖南启元律师事务所（以下简称"本所"）接受湖南汉森制药股份有限公司 （以下简称"公司"）的委托，指派本所律师出席公司 2024 年年度股东大会（以 下简称"本次股东大会"），对本次股东大会的召集和召开程序、出席会议人员及 召集人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表本 法律意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人 民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》等我国现行 法律、法规、规范性文件以及《湖南汉森制药股份有限公司章程》（以下简称"《公 司章程》"）的有关规定出具本法律意见书。 本所律师声明如下： （一）本所律师根据本法律意见书出具日以前 ...

Core Insights - The company achieved a total revenue of 1.004 billion yuan in 2024, marking a year-on-year growth of 5.12% [1][4] - Net profit attributable to shareholders was 220 million yuan, with a year-on-year increase of 7.43%, but the growth rate significantly slowed compared to 2023 [1][4] - The growth rate of non-recurring net profit dropped from 22.97% in 2023 to 2.89% in 2024, indicating a weakening in the company's profitability excluding non-recurring items [1][4] Revenue and Profit Performance - The company's total revenue surpassed 1 billion yuan for the first time, driven by the sustained promotion of core products and optimization of sales channels [4] - However, the slowdown in net profit growth raises concerns, with a decline from 22.31% in 2023 to 7.43% in 2024 [4] - Rolling quarter-on-quarter data shows total revenue grew by 4.05%, while net profit and non-recurring net profit experienced negative growth of -2.56% and -6.14%, respectively [4] Core Product Performance - Core products such as Si Mo Tang oral liquid and Suo Quan capsules performed well in the market, with Si Mo Tang being a unique product under the national medical insurance directory [4] - The company secured selection in multiple centralized procurement projects, reinforcing its market position [4] - Other products like Suo Quan capsules and Tian Ma Xing Nao capsules have also entered various county-level medical community directories, indicating successful market penetration [4] Market Challenges - The company faces significant market pressure due to deepening medical insurance reforms and the expansion of centralized procurement, which may lead to price reductions and profit margin compression [5] - Ongoing medical anti-corruption efforts impose higher compliance requirements on the company's marketing strategies, making it crucial to maintain competitiveness while adhering to regulations [5] R&D Investment Trends - R&D investment decreased to 39.32 million yuan in 2024, a decline of 7.28% year-on-year, with R&D expenditure accounting for 3.91% of total revenue, down 0.53 percentage points from 2023 [6] - The reduction in R&D spending could hinder the launch of new products and upgrades of existing ones, potentially weakening market competitiveness [6] - Despite some achievements in R&D, such as obtaining registration certificates for certain products, the overall decline in investment raises concerns about future growth [6] Overall Assessment - The company maintained revenue and net profit growth in 2024, but the slowdown in growth rates and decline in R&D investment highlight challenges in adapting to market competition and policy changes [6] - Future strategies should focus on enhancing core product competitiveness, increasing R&D investment, and optimizing cost structures for sustainable development [6]

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, with no false records or significant omissions [2][3] - The quarterly report has not been audited [3][11] Financial Data Summary - Cash and cash equivalents decreased by 39,733,803.29 yuan, a decline of 31.04%, primarily due to the purchase of new bank wealth management products [5] - Trading financial assets increased by 85,547,723.78 yuan, a growth of 35.04%, attributed to increased purchases of bank wealth management products [5] - Contract liabilities decreased by 1,175,424.99 yuan, a decline of 43.17%, due to a reduction in payments received related to sales contracts [5] - Employee compensation payable decreased by 21,782,047.41 yuan, a decline of 54.81%, mainly due to the distribution of last year's year-end bonuses [5] - Other current liabilities increased by 19,808,881.52 yuan, a growth of 157.76%, due to an increase in endorsed bank acceptance bills [5] - Other comprehensive income decreased by 21,337,283.83 yuan, a decline of 70.07%, due to a reduction in the other comprehensive income of associates accounted for using the equity method [5] - Management expenses increased by 6,865,983.25 yuan, a growth of 56.21%, due to increased expenses for annual meetings and business hospitality [5][6] - Financial expenses decreased by 159,438.54 yuan, a decline of 38.82%, due to reduced bank loans and interest expenses [6] - Other income decreased by 1,661,762.99 yuan, a decline of 60.78%, due to a reduction in government subsidies received [6] - Investment income decreased by 49,866,535.38 yuan, a decline of 1087.13%, primarily due to a decrease in investment income from associates [6] - Net profit decreased by 47,007,509.82 yuan, a decline of 80.68%, mainly due to reduced investment income from associates [7] - Net cash flow from operating activities increased by 28,903,273.80 yuan, a growth of 140.97%, due to reduced cash payments for goods and services [7] - Net cash flow from investing activities decreased by 90,110,004.98 yuan, a decline of 6777.25%, due to increased cash payments for bank wealth management products [8] - Net cash flow from financing activities decreased by 2,192,009.64 yuan, a decline of 119.68%, due to previous year's funding received by a subsidiary [8] - The net increase in cash and cash equivalents decreased by 63,398,740.82 yuan, a decline of 267.90%, due to changes in cash flows from operating, investing, and financing activities [8]

Group 1 - The company held the sixth board meeting and the seventh supervisory board meeting on April 24, 2025, to review and approve the 2024 profit distribution plan, which will be submitted to the 2024 annual general meeting for approval [1][4]. - The audit committee found that the profit distribution plan aligns with the company's actual situation and does not harm the interests of shareholders, especially minority shareholders [1][3]. - The board of directors believes the profit distribution plan considers the company's current and future investment needs and is beneficial for the company's normal operations and healthy development [2][3]. Group 2 - The company achieved a net profit attributable to shareholders of 220,244,409.11 yuan for 2024, with the parent company reporting a net profit of 152,528,625.53 yuan [5]. - The profit distribution plan proposes not to distribute cash dividends, issue bonus shares, or increase capital from reserves, with undistributed profits carried forward to the next year [5][6]. - The decision to not distribute dividends is based on the company's development strategy and the need to maintain operational stability and risk resilience [6]. Group 3 - The company approved the use of idle self-owned funds for cash management, with a limit of up to 400 million yuan to purchase low-risk financial products or structured deposits [9][10]. - The purpose of this cash management is to enhance the efficiency of fund usage without affecting normal operations, thereby increasing returns for the company and its shareholders [9][10]. - The board and supervisory board agreed that the current financial situation is stable, and the proposed cash management will not adversely affect the company's operations [17][38]. Group 4 - The supervisory board meeting also approved the 2024 annual financial settlement report, which reflects the company's financial status and operating results accurately [28][31]. - The internal control evaluation report for 2024 was approved, indicating no significant deficiencies in the internal control system [37]. - The company will implement the cash management decision within a 12-month period from the approval date [13].

资产评估报告 北京亚超评报字（2025）第 A110 号 北 京 亚 超 资 产 评 估 有 限 公 司 BeijingYaChaoAsset s AppraisalCo.,Ltd. 本资产评估报告依据中国资产评估准则编制 湖南汉森制药股份有限公司因编制财务报告需要 进行商誉减值测试涉及云南永孜堂制药有限公司、云 南康佰佳医药有限公司 资产组（含商誉）可收回金额 (共 2 册，第 1 册) 二零二五年四月十八日 公司地址：北京市海淀区复兴路 47 号天行建商务大厦 20 层 2202 邮编：100036 电话：（010）51716863 | 资产评估报告声明 1 | | | | --- | --- | --- | | 资产评估报告摘要 | | 3 | | 资产评估报告正文 | | 7 | | 一、 | 绪言 | 7 | | 二、 | 委托人、 CGU | 产权持有单位和资产评估委托合同约定的其他资产评估报告使用人 | | 概况 | 8 | | | 三、 | 评估目的 | 22 | | 四、 | 评估对象和评估范围 | 23 | | 五、 | 价值类型 | 41 | | 六、 | 评估基准日 | 42 | | ...

关于湖南汉森制药股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表的 专项审核报告 众环专字(2025)1100174号 关于湖南汉森制药股份有限公司 非经营性资金占用及其他关联资金往来情况汇总表 的专项审核报告 （此页无正文，为关于湖南汉森制药股份有限公司非经营性资金占用及其他关联资金往来情 况汇总表的专项审核报告众环专字(2025)1100174号签章页） 中审众环会计师事务所（特殊普通合伙） 中国注册会计师： 众环专字(2025)1100174 号 湖南汉森制药股份有限公司全体股东： 我们接受委托，在审计了湖南汉森制药股份有限公司（以下简称"汉森制药公司"）2024 年 12 月 31 日合并及公司的资产负债表，2024 年度合并及公司的利润表、合并及公司的现 金流量表和合并及公司的股东权益变动表以及财务报表附注的基础上，对后附的《上市公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》（以下简称"汇总表"）进 行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号——上市公 司资金往来、对外担保的监管要求》的规定，编制和披露汇总表、提供真实、合法、完整的 审 ...